pharmaphorum

DECEMBER 23, 2022

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). And in 2023, these investments will hopefully pay off. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”.

Marketing 87

Marketing Sales Medical Patients 87

European Pharmaceutical Review

MAY 2, 2023

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. Previously, he spent more than 10 years at Roche in multiple positions within medical affairs. cited 2023 Apr 4]. 2019 [cited 2023 Apr 4]. cited 2023 Apr 4].

Patients 94

Patients Medicine Marketing Medical 94

European Pharmaceutical Review

DECEMBER 28, 2023

Can you share some highlights from the data presented at ASH 2023? The IND for the combination was cleared in May 2023 and we have now treated patients in the first two cohorts. In addition, we have received Fast Track designation by the FDA in September 2023 highlighting the impact this combination treatment can have for patients.

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

PM360

OCTOBER 13, 2023

This cookie-less marketing yields promising results with an 84% reduction in cost per acquisitions (CPAs) and a 3x increase in impressions served when compared to leading contextual solutions. These include text and code generation, automated lead generation, music composition, and even personalized speech and video creation.

Marketing 64

Marketing Specialization Healthcare Healthcare 64

Impetus Digital

APRIL 24, 2023

Piliero predicted several major change points for Medical Science Liaisons (MSLs), including: MSLs will engage a broader range of external stakeholders beyond traditional physicians, including nurses, physician assistants, patients, academics, payers and policymakers, and digital opinion leaders (DOLs).

Medical 52

Medical Education Physicians Healthcare 52

Pharmaceutical Technology

NOVEMBER 21, 2022

Meanwhile, the drug's closest TIL competitor, Iovance Biotherapeutics’ lifileucel, has begun a rolling BLA for advanced melanoma patients and could reach the market as early as Q3 2023. In April this year, the FDA provided new feedback on the potency assays, which Iovance indicated will be addressed in the latest BLA.

Manufacturing 59

Manufacturing Food and Drug Administration Medical science Patients 59

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. This trial is anticipated to begin in the second half of 2023.

Food and Drug Administration 83

Food and Drug Administration Manufacturing Safety Pharmaceutical 83